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Essay
Difficulties in Meeting the 
Demands of Regulators and 
Guidelines
In Europe, it is a legal requirement to 
conduct clinical trials in accordance 
with the International Conference on 
Harmonisation’s guidelines on good 
clinical practice (see http://www.ich.
org/). A recent editorial reported that 
this directive has led to a decline in the 
number of trials being conducted by 
independent academic groups [1]. One 
possible reason for this is that reporting 
and documentation requirements are 
now so burdensome that the process 
has become unnecessarily complicated 
[2]. This is rather ironic, given that 
well-designed clinical trials should 
be amenable to very simple data 
handling and analysis [3]. Indeed the 
ﬂowchart established by the CONSORT 
(Consolidated Standards of Reporting 
Trials) statement [4] for carrying out 
a properly randomised controlled trial 
has just four steps, which supports the 
approach of keeping it simple. 
Following discussions with colleagues 
at various institutions (including 
Oxford University, the London School 
of Hygiene and Tropical Medicine, the 
International Aids Vaccine Initiative, 
and the Medical Research Councils of 
Uganda, South Africa, and the United 
Kingdom), one major difﬁculty comes 
up time after time: these, and many 
other, clinical trial groups do not have 
the skills or resources to establish 
and use software systems required 
to manage trial data in compliance 
with the International Conference 
on Harmonisation’s guidelines. This 
situation is further exacerbated for 
non-commercial research groups based 
in developing countries, where basic 
information systems infrastructure and support tends to be even more limited 
[5].
There is little good independent 
information about what is available. 
Additionally, there is almost a complete 
absence of guidance from regulatory 
agencies such as the European 
Medicines Agency and United States 
Food and Drug Administration about 
how to evaluate the many competing 
systems available, and indeed what 
the actual requirements are for 
trials where the data will be needed 
for a regulatory submission. This is 
particularly important with respect to 
trials evaluating products for neglected 
diseases, which are often carried out 
by academic researchers and where 
the data would be needed to support a 
product license. The size of this issue 
can be somewhat ascertained from 
the results of a search that we did at 
the World Health Organization trials 
registration site (http://www.who.
int/trialsearch/, accessed September 
27, 2007): use of the term “Africa” 
returned 206 trials, and the term “Asia” 
returned 520. 
Ideally, such a system would 
work as well for a single-centred 
investigator-led small trial as it would 
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Box 1. An Introduction to Open-
Source Software: Definitions 
and Required Reading 
1. Ten Things You Didn’t Know about 
Open Source (http://www.tectonic.
co.za/view.php?id=1465)
2. Definition of Open-Source Software 
a. Free redistribution
b. Source code
c. Derived works
d. Integrity of the author’s source 
  code
e. No discrimination against persons 
  or groups
f. No discrimination against fields of 
  endeavour
g. Distribution of license
h. License must not be specific to a 
  product
i. License must not restrict other 
  software
j. License must be technology-neutral
Taken from Opensource.org. See http://
opensource.org/docs/definition.php for 
an annotated description of the above 
points.
3.  “The Cathedral and Bazaar” by Eric 
S. Raymond (http://www.firstmonday.
org/issues/issue3_3/raymond/). A 
seminal essay by a professional 
software developer that outlines his 
transition from open-source sceptic to 
advocate.
4. Fork: a substantial modification of a 
software system that takes it in a new 
direction. See http://en.wikipedia.org/
wiki/Fork_(software_development) for 
more details.
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for large regulatory standard multi-
centred randomised controlled trials. 
Furthermore, this system would need to 
be affordable to the public sector and 
modiﬁable and amenable for use with 
existing software already employed, 
particularly statistical and reporting 
software. This is quite a tall order. Put 
in this context, and considering the 
dialogue between research groups on 
this matter, it would seem prudent 
for international health research 
organisations to combine their efforts 
and spending power and assist with 
the development of systems that are 
open to all and truly ﬁt for purpose. 
The daunting challenges of capturing, 
cleaning, extracting, and storing trial 
data would then be eased, with the 
added desirable beneﬁt of improving 
quality and reliability of data. Perhaps 
we would then see more academics 
wanting to conduct clinical research.
The Cost, Complexity, and 
Availability of Current Systems
It has been noted [6] that clinical 
trials–related software can be 
prohibitively expensive, especially 
for individual researchers, or groups 
based in developing countries. The 
two most commonly used packages 
[7], Oracle Corp’s Oracle Clinical 
(http://www.oracle.com/industries/
life_sciences/oracle-clinical.html) and 
Phase Forward’s Clintrial (http://www.
phaseforward.com/products/clinical/
cdm/cis/), are both designed for use 
with commercial database systems. 
Investing in such systems would cost 
in the range of hundreds of thousands 
of dollars, depending on the size 
of the trial and number of licenses 
needed. Such costs would take up a 
disproportionate amount of a typical 
non-commercial trial budget, which 
is generally in the same order of 
magnitude as the cost of these systems, 
and must cover everything required by 
the trial. This leads many developing 
country institutions with the unenviable 
choice of either not being able to 
comply with international standards or 
having to send case report forms off-site 
for processing. This lamentable state 
of affairs has been acknowledged by 
some funding groups, such as the Gates 
Foundation–supported Malaria Clinical 
Trials Alliance [8], the European and 
Developing Countries Clinical Trials 
Partnership, and the African Malaria 
Network Trust; however, addressing 
the need for an affordable, easy-to-use 
clinical trial data-management system is 
currently beyond the scope and remit 
of the capacity-building activities being 
rolled out by such groups.
An Early Attempt to Address the 
Gap
Cynthia Brandt and Prakash Nadkarni 
of the Yale Center for Medical 
Informatics, with their TrialDB system 
(http://ycmi.med.yale.edu/trialdb/),
have championed a non-commercial 
approach since the 1990s [9]. 
However, although their software is 
freely available, its use is targeted to 
either Oracle’s Database Management 
System or Microsoft’s SQL Server for 
case report form generation and data 
capture and management. Whilst 
this “free” system is a good starting 
point for those who may already 
have the appropriate licensing and 
expertise for the required commercial 
components, its use in resource-
poor countries and by individual 
researchers is likely to be limited. 
However, it is not inconceivable 
that this application could be re-
engineered to take advantage of 
the free (for non-commercial use) 
and open-source database systems 
such as MySQL (http://www.mysql.
org/) and PostgreSQL (http://www.
postgresql.org/). Such an initiative 
could be funded by international 
health agencies for minimal outlay. 
Just as funders of biomedical research 
are starting to require scientiﬁc 
output to be published in open-access 
journals, could they not require that 
the software used for the management 
of clinical trials also be open? Even for 
commercial research organisations, 
such an approach can only be to 
their longer-term beneﬁt, given the 
likely savings they would incur due to 
reduced software costs.
A Way Forward?
We propose a commitment by the major 
international donor and implementing 
groups to encourage efforts to 
develop a free and open-source data-
management system for clinical trials 
that adheres to evolving standards such 
as those set by CDISC (the Clinical Data 
Interchange Standards Consortium; 
http://www.cdisc.org). We believe 
that an open-source approach has 
the best chance of ensuring that all 
kinds of groups can be involved with 
the development of systems that have 
bearing on global public health.
The US National Institute of 
Health’s National Cancer Institute 
has a wide-ranging, quickly evolving, 
and very open-source friendly [10] 
initiative called CaBIG (Cancer 
Biomedical Informatics Grid), which 
includes clinical trials management 
systems, amongst others (see [11]). 
One of the many projects involved in 
CaBIG, OpenClinica (http://www.
openclinica.org/), has used CaBIG as 
a springboard to launch and maintain 
a free and open-source clinical trials 
data-management system. This software 
is entirely built using open and free 
systems and programming languages. 
Such a system might be the basis for 
creating a “forked” solution (see Box 
1) to ﬁt the needs of those working 
on diseases of poverty in developing 
countries. In line with Oliveira and 
Salgado [12], we believe that a web-
based solution to the complexities 
of running trials (especially multi-
centre ones) and processing data 
is appropriate, as it reﬂects the 
information and technology expertise 
available globally that could be better 
used to support those engaged in 
clinical research. Other advantages of 
web-based systems are that they support 
simultaneous data entry from multiple 
sites and run using standard web 
browsers. Web-based technologies are 
rapidly being adopted in countries such 
as Kenya, where we are based. Here, as 
in many developing countries, there is 
a newly educated generation including, 
but not limited to, skilled computer 
scientists and informaticians, who will 
not only be passive recipients of such 
software but also become the future 
architects, developers, and maintainers 
of such systems. Individual researchers 
in any organisation should be able 
to more readily make use of such 
systems through standard information 
technology support provided by their 
employing organisation or institution.
Conclusions
Although we perceive the need for the 
above-advocated approach to be most 
profound in developing countries and 
for those researchers working on small-
to-large multi-centre non-commercial 
projects, if implemented correctly, its 
impact surely can only be beneﬁcial 
to all clinical researchers. There are 
many examples of how open-source 
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approaches have been used to assist 
scientiﬁc and biomedical research. 
Indeed, one eminent proponent of 
the open-source approach has even 
gone so far as to claim that PERL 
(an open-source language) saved the 
human genome project [13]. Another 
example that relates to medical 
research is Thomson International’s 
well-known and widely used EndNote 
referencing software, which now relies 
on a commercial licensing of the power 
of the open-source MySQL database 
system. A good mainstream example 
might also support our point. Most of 
us, each and every day, utilise Web sites 
driven by the open-source Apache web 
server, which is the most common web 
server and has had over 50% of market 
share since 1998 [14]. 
Research organisations and funders 
should combine efforts to produce 
an open-source solution for trial data 
management. A shared platform could 
then be easily established, and would 
bring wider beneﬁts such as electronic 
submission to regulators, automated 
sharing of data, and contribution 
to important public databases such 
as pharmacovigilance and drug-
monitoring registries.
We believe that an open-source 
approach to a truly designed-for-
purpose data-management system for 
clinical trials is attractive. Such a system 
would save money by eliminating 
the reliance on the use of expensive 
database software systems and their 
administrators. This would empower 
and enable a wider variety of people 
to conduct trials, as the question of 
capturing, cleaning, and extracting 
data would not be overly daunting or 
expensive. This point is signiﬁcant, as 
it may encourage more investigators 
in resource-poor settings to take part 
in high-standard research that would 
otherwise be out of reach and beyond 
their capacity. Surely this would 
increase the scope and variety of trials 
that are conducted. Our hope for this 
article is that it will begin a debate 
on this topic, and lead to a concerted 
effort to lobby the international 
research and donor community to 
make sure this barrier to trial conduct 
is understood and addressed. 
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